All In Biotech

Drug Trial Radar · NCT06553339

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

A Phase I Study of HS-10516 in Patients With VHL Syndrome Associated Tumors,to Investigate Safety, Tolerance, Pharmacokinetic and Efficacy

Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 19, 2024

Primary completion

Jul 31, 2026

Study completion Jul 31, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.

Conditions

  • Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma

Interventions

  • Oral HS-10516Drug

    Oral HIF-2α inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: MTD/MAD of HS-10516Time frame: Approximately 2 months
  2. Phase Ib: Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Approximately 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.